Lung Cancer Clinical Trial

Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Summary

The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed small cell lung cancer diagnosis
Diagnosis made with excisional or core needle biopsy specimen (fine needle aspirate may be permitted with approval from the PI)
Subjects must submit fresh or archived FFPE tumor sample to the central laboratory
ECOG performance status of 0 or 1 at time of enrollment
Planned extensive stage first-line therapy of etoposide plus carboplatin plus PD-L1 inhibitor (atezolizumab or durvalumab)
Extensive stage disease at time of diagnosis
Willing and able to provide informed consent

Exclusion Criteria:

History of prior systemic treatment of SCLC
History of radiotherapy or planned radiotherapy to all measurable disease foci
Prior diagnosis of non-small cell lung cancer
Mixed small cell and non-small cell histology
Suspected metastatic cancer from other sites (i.e., those without a known or suspected lung primary diagnosis)
Not willing to have additional blood samples collected

Study is for people with:

Lung Cancer

Estimated Enrollment:

50

Study ID:

NCT05257551

Recruitment Status:

Recruiting

Sponsor:

Tempus Labs

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Cancer and Blood Specialty Clinic
Los Alamitos California, 90720, United States More Info
Trong Nguyen
Contact
562-735-0602
Nihal Abdulla, MD
Principal Investigator
Illinois Cancer Care
Peoria Illinois, 61615, United States More Info
Trupti Hattiangadi
Contact
309-243-3000
Mohammad (Fahad) Asad, MD
Principal Investigator
Englewood Health Medical Center
Englewood New Jersey, 07631, United States More Info
Hauwa Adeniji
Contact
201-608-2846
Meghan Kaumaya, MD
Principal Investigator
TriHealth Cancer Institute
Cincinnati Ohio, 45220, United States More Info
Wayne Thompson
Contact
513-865-5020
James Maher, MD
Principal Investigator
OhioHealth Research Institute
Columbus Ohio, 43214, United States More Info
Hazel Antao
Contact
614-788-3880
Arvinder Bhinder, MD
Principal Investigator
Oklahoma Cancer Specialists and Research Institutes
Tulsa Oklahoma, 74146, United States More Info
Stephanie Sandoval
Contact
918-505-3201
Paul Zito, MD
Principal Investigator
Cancer Care Association of York
York Pennsylvania, 17403, United States More Info
Jennifer Stough
Contact
Contact
717-741-9229
Chanh Huynh, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

50

Study ID:

NCT05257551

Recruitment Status:

Recruiting

Sponsor:


Tempus Labs

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.